Causes of death in HIV-infected French drug users, 1995-2000;Causes de décès chez les usagers de drogues Français infectés par le VIH, 1995-2000

Annales de Medecine Interne

Volumn 153, Issue 7 SUPPL. 1, 2002, Pages

  Lewden, Charlotte ^a   Bonnet, Fabrice ^b   Bevilacqua, Sibylle ^c   Heripret, Laurence ^d   May, Thierry ^c   Morlat, Philippe ^b   Jougla, Eric ^a   Dabis, François ^a   Chêne, Geneviève ^a   Salmon, Dominique ^e   Bernard, N ^f   Lacoste, D ^f   Malvy, D ^f   Neau, D ^f   Dupon, M ^f   Moreau, J F ^f   Mercie P ^f   Pellegrin, J L ^f   Ragnaud, J M ^f   Commenges, D ^f   Jacqmin Gadda, H ^f   Thiebaut R ^f   Lawson Ayayi, S ^f   Lavignolle, V ^f   Blaizeau, M J ^f   Decoin, M ^f   Formaggio, A M ^f   Delveaux, S ^f   Labarerre, S ^f   Uwamaliya, B ^f   Palmer, G ^f   Touchard, D ^f   Dutoit, D ^f   Pereira, F ^f   Boulant, B ^f   Beylot, J ^f   Bonarek, M ^f   Coadou, B ^f   Gelie, P ^f   Jaubert, D ^f   Nouts, C ^f   Dutronc, H ^f   Cipriano, G ^f   Lafarie, S ^f   Lacut, J Y ^f   Mercie, P ^f   Tchamgoue, S ^f   Viallard, J F ^f   Faure, I ^f   Rispal, P ^f   Cipriano, C ^f   Leng, B ^f   Le Bras, M ^f,f   Djossou, F ^f   Pivetaud, J P ^f   De La Taille, C ^f   Galperine, T ^f   Ochoa, A ^f   Chambon, D ^f   Fleury, H ^f   Masquelier, B ^f   Pellegrin, I ^f   Bonnal, F ^f   Farbos, S ^f   Loste, M ^f   Caunegre L ^f   Ceccaldi, J ^f   Buy, E ^f   Brossard, G ^f   Salamon, R ^f   Yeni P ^f   Delfraissy, J F ^f   Leport, C ^f   Heripret L ^f   Bevilacqua S ^f   Dellac, M ^f   Dutoit, S ^f   Mazou, V ^f   Imbert, Y ^f   Allegre T ^f   Marquiant, M ^f   Abino, J F ^f   Barel, P ^f   Lagier, A ^f   Schmit, J L ^f   Denoeux, J P ^f   Poulain, H ^f   Chennebault, J M ^f   Loison, J ^f   Bru, J P ^f   Gaillat, J ^f   Dupont, A ^f   Pulik, M ^f   Berbar, J F ^f   Lepeu, G ^f   Guglielminotti, C ^f   more..

^a INSERM   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c CHU NANCY BRABOIS   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e CépiDC INSERM ^*  (France)

^f Hôpital Cochin ^*

Author keywords

Cause of death; Drug users; HIV infection

Indexed keywords

ACCIDENT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; CANCER; CAUSE OF DEATH; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FRANCE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL INFORMATION SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTOXICATION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SMOKING; SOCIAL STATUS; SUICIDE; T LYMPHOCYTE;

ADULT; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS;

EID: 0036868219     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet, 1998; 352: 1725-30.
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération Nationale des Centres de Lutte contre le SIDA. AIDS, 1997; 11: F101-5.
3. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). J Acquir Immune Defic Syndr Hum Retrovirol, 1998; 18: 358-64.
4. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr, 1999; 22: 369-78.
5. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS, 1999; 13: 2547-54.
6. Lewden C, Raffi F, Chêne G, Sobel A, Leport C, The Aproco Study Group. Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy. Standardization to the general population. J Acquir Immune Defic Syndr, 2001; 26: 480-2.
7. Marimoutou C, Chêne G, Dabis F, Lacoste D, Salamon R, Le Groupe D'Epidémiologie Clinique Du Sida En Aquitaine (GECSA). L'infection par le virus de l'immunodéficience humaine et le SIDA en Aquitaine, dix ans d'expérience d'un système d'information hospitalier, 1985-1995. Presse Med, 1997; 26: 703-10.
8. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR, 1992; 41: 1-19.
9. Valdez H, Chowdhry TK, Asaad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: Analysis of 260 deaths during 1995-1999. Clin Infect Dis, 2001; 32: 1487-93.
10. Van Haastrecht HJ, Van Ameijden EJ, Van Den Hoek JA, Mientjes GH, Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol, 1996; 143: 380-91.
11. Sorensen JL, Jacob C, Dilley J, Corey V, Yee N. Causes of death among substance users with HIV disease. AIDS, 2000; 14: 2047-9.
12. Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS, 2000; 14: 1829-37.
13. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis, 2001; 32: 1207-14.
14. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis, 2001; 32: 492-7.
15. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr, 1993; 6: 602-10.
16. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology, 1999; 30: 1054-8.
17. Rancinan C, Neau D, Savès M, et al. Is hepatitis C coinfection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS, 2002; 16: 1357-62.
18. Rodriguez-Rosado R, Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Management of hepatitis C in HIV-infected persons. Antivir Res, 2001; 52: 189-98.
19. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet, 2000; 356: 1800-5.
20. Tyndall MW, Craib KJP, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr, 2001; 28: 351-7.